JPMorgan Chase & Co. Lowers United Therapeutics (NASDAQ:UTHR) Price Target to $355.00

United Therapeutics (NASDAQ:UTHR - Free Report) had its price target decreased by JPMorgan Chase & Co. from $357.00 to $355.00 in a research note issued to investors on Monday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biotechnology company's stock.

Other analysts have also issued research reports about the company. Bank of America upgraded United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price target for the company in a report on Monday, April 21st. UBS Group upped their target price on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. HC Wainwright reissued a "buy" rating and set a $425.00 price target on shares of United Therapeutics in a research report on Thursday, February 27th. Finally, StockNews.com upgraded United Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Thursday, April 17th. Four investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $390.17.

United Therapeutics Stock Performance

Shares of UTHR traded down $5.04 during mid-day trading on Monday, hitting $291.38. 311,498 shares of the stock were exchanged, compared to its average volume of 448,048. The company has a market cap of $13.09 billion, a PE ratio of 12.80, a price-to-earnings-growth ratio of 0.97 and a beta of 0.63. United Therapeutics has a 52-week low of $233.31 and a 52-week high of $417.82. The firm has a 50-day moving average of $308.67 and a two-hundred day moving average of $346.48.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping the consensus estimate of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. During the same quarter last year, the business posted $4.36 earnings per share. On average, sell-side analysts predict that United Therapeutics will post 24.48 EPS for the current year.

Insider Buying and Selling

In other United Therapeutics news, Director Raymond Dwek sold 3,000 shares of United Therapeutics stock in a transaction on Monday, April 21st. The shares were sold at an average price of $285.57, for a total transaction of $856,710.00. Following the sale, the director now owns 1,750 shares of the company's stock, valued at $499,747.50. The trade was a 63.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Tommy G. Thompson sold 2,500 shares of the business's stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the transaction, the director now owns 8,480 shares in the company, valued at $2,703,424. The trade was a 22.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 84,500 shares of company stock worth $28,179,150 in the last 90 days. Insiders own 11.90% of the company's stock.

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Parallel Advisors LLC boosted its holdings in United Therapeutics by 2.8% during the 4th quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company's stock valued at $385,000 after acquiring an additional 30 shares during the period. Signaturefd LLC lifted its position in shares of United Therapeutics by 4.7% during the fourth quarter. Signaturefd LLC now owns 663 shares of the biotechnology company's stock worth $234,000 after purchasing an additional 30 shares in the last quarter. Anchor Investment Management LLC boosted its stake in shares of United Therapeutics by 12.0% in the fourth quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock valued at $99,000 after purchasing an additional 30 shares during the period. Great Lakes Advisors LLC boosted its stake in shares of United Therapeutics by 1.6% in the fourth quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company's stock valued at $697,000 after purchasing an additional 31 shares during the period. Finally, Oregon Public Employees Retirement Fund grew its holdings in shares of United Therapeutics by 0.4% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company's stock valued at $3,214,000 after purchasing an additional 33 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.